Pharmaceutical Companies; Prometheus Laboratories and UCLA Sign Agreement to Validate Biological Mar...
Pharmaceutical Companies; Prometheus Laboratories and UCLA Sign Agreement to Validate Biological Markers of Mucosal Healing in IBD
About this item
Full title
Publisher
Atlanta: NewsRx
Journal title
Language
English
Formats
Publication information
Publisher
Atlanta: NewsRx
Subjects
More information
Scope and Contents
Contents
"Adding this research project to our R&D portfolio is the latest in a series of investments Prometheus has made to answer the clinical questions related to optimization of the use of biologic therapies commonly used in IBD treatment," said Joseph M. Limber, President & Chief Executive Officer of Prometheus. "Our goal is to be able to answer the cli...
Alternative Titles
Full title
Pharmaceutical Companies; Prometheus Laboratories and UCLA Sign Agreement to Validate Biological Markers of Mucosal Healing in IBD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_817665909
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_817665909
Other Identifiers
ISSN
1531-6386
E-ISSN
1532-4664
